2care4 Generics ApS
Nøgletal
- Afkastningsgrad
- 17 %
- Egenkapitalforrentning
- 21,8 %
- Likviditetsgrad
- 211,6 %
- Soliditetsgrad
- 60,7 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | 58.190.000 |
Driftsresultat | 22.056.000 |
Finansielle indtægter | 1.567.000 |
Finansielle omkostninger | 1.618.000 |
Skat af årets resultat | 4.812.000 |
Årets resultat | 17.193.000 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 28 |
Personaleomkostninger | 30.346.000 kr. |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 2.125.000 |
Kortfristede aktiver | 86.496.000 |
Langfristede aktiver | 43.242.000 |
Aktiver i alt | 129.738.000 |
Egenkapital | 78.737.000 |
Forpligtelser i alt | 51.001.000 |
Kortfristede forpligtelser | 40.878.000 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Varebeholdninger | 55.748.000 |
Tilgodehavender fra salg og tjenesteydelser | 21.121.000 |
Andre kortfristede tilgodehavender | 1.253.000 |
Leverandørgæld | 8.387.000 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 50.000 |
Overført resultat | 46.892.000 |
Foreslået udbytte | 0 |
Investeringer og aktiver
| Regnskabsperiode | |
|---|---|
Langfristede investeringer og tilgodehavender | 121.000 |
Materielle anlægsaktiver | 348.000 |
Højdepunkter fra årsrapporten
Forretning og udvikling
The Main activity of the company is to develop, import, produce and export generic pharmaceutical products.
The income statement of the Company for 2024 shows a profit of DKKm 17,2, and at 31 December 2024 the balance sheet of the Company shows a positive equity of DKKm 78,7.
For the financial year 2025 the company expects slightly increased activity, and a net profit level in line with 2024 Research and development The development of the company includes implemented measures that within a few years in expected to generate increased revenue for the company. External environment The energy consumption and general environmental footprint from the 2care4 Generics activities are very limited and has limited impact on the surrounding environment. Since the medical products are purchased as commodities, the Company has little opportunity to assess and evaluate impacts on the environment in the supply chain. This given that there is no contact with the original producer as such and, therefore, the Company has no influence on the production phase at all.In our opinion…
The Generics business has performed below expectations in 2024 driven by supply constraint on several key product lines.
Risici og væsentlige forhold
There has been no uncertainty regarding recognition and measurement in the Annual Report.
No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.
Forpligtelser og sikkerhedsstillelser
Rental and lease obligations The following assets have been placed as security for rent obligations for a period of 6 months. 312000 286000 Other contingent liabilities The group companies are jointly and severally liable for tax on the jointly taxed incomes etc of the Group. The total amount of corporation tax payable is disclosed in the Annual Report of 2care4 Group ApS, which is the management company of the joint taxation purposes. Moreover, the group companies are jointly and severally liable for Danish withholding taxes by way of dividend tax, tax on royalty payments and tax on unearned income. Any subsequent adjustments of corporation taxes and withholding taxes may increase the Company's liability.
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger